Rain Therapeutics Inc. (RAIN)

$3.94

-0.46 (-10.45%)
Rating:
Recommendation:
-
Symbol RAIN
Price $3.94
Beta 0.000
Volume Avg. 0.07M
Market Cap 104.665M
Shares () -
52 Week Range 2.15-17.31
1y Target Est -
DCF Unlevered RAIN DCF ->
DCF Levered RAIN LDCF ->
ROE -58.24% Strong Sell
ROA -64.53% Strong Sell
Operating Margin -
Debt / Equity 12.59% Neutral
P/E -
P/B 1.06 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest RAIN news


Mr. Avanish Vellanki M.B.A.
Healthcare
Biotechnology
NASDAQ Global Select

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.